Company news

Mirum Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

January 12, 2025

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

November 13, 2024

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

November 3, 2024

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

October 30, 2024

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

October 9, 2024

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 6, 2024

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

July 30, 2024

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

July 24, 2024

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

July 7, 2024

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

June 27, 2024

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

June 16, 2024

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

June 15, 2024

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

June 5, 2024

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 30, 2024

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 28, 2024

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 17, 2024

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 6, 2024

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

May 6, 2024

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

April 30, 2024

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

April 1, 2024

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

March 12, 2024

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

February 28, 2024

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

February 27, 2024

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

February 20, 2024

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

January 15, 2024

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

January 7, 2024

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

December 17, 2023

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

November 19, 2023

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

November 12, 2023

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

November 2, 2023

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

October 29, 2023

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

October 26, 2023

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

October 16, 2023

Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

October 6, 2023

Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

October 1, 2023

Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

September 25, 2023

Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

September 20, 2023

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

September 10, 2023

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 4, 2023

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

September 4, 2023

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

July 26, 2023

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

July 24, 2023

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 16, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.